Chase Neumann
@OncNTechStuff
Followers
376
Following
1K
Media
14
Statuses
230
Oncology @ Recursion ($RXRX) | ex-@ClevelandClinic | Boise State Alum | Heart for Folks with Disabilities | Comments are my own
SLC, UT
Joined October 2022
In recent earnings, Recursion shared more details about our RBM39/REC-1245 program. In the video below, I share how the Recursion platform accelerated our RBM39 program and uncovered novel biology along the way. Check it out to learn more!
💡 Explain the Impact: Using data & AI to deliver a new cancer drug to clinic twice as fast as industry average Chase Neumann, PhD (@OncNTechStuff), Associate Director of Oncology, shares how we used the Recursion OS to discover new ways to target aggressive cancers and identify
0
0
7
🚀 Big news from @RecursionPharma! Our 2nd Neuroscience Phenomap — a whole-genome map of the brain’s immune cells 🧠 — has been accepted by @Roche & @genentech, triggering a $30M milestone! A massive step toward decoding biology to radically improve lives. 💥 #TechBio #AI
7
31
168
I talk a lot about the incredible platform we’re building at @RecursionPharma, but nothing beats hearing from the brilliant scientists who use it every day. That’s why I love this video with @OncNTechStuff. Chase is part of the team that uncovered the initial insight for our
💡 Explain the Impact: Using data & AI to deliver a new cancer drug to clinic twice as fast as industry average Chase Neumann, PhD (@OncNTechStuff), Associate Director of Oncology, shares how we used the Recursion OS to discover new ways to target aggressive cancers and identify
7
1
26
Phenomenal lab looking for a postdoc in Salt Lake!
🚨Postdoctoral position available now! 🚨We have an immediate fully funded position available in cardiac metabolism. We are looking for a highly motivated person to lead our animal model work in oxidative metabolism in heart! Pay is competitive with benefits offered. 1/2
0
1
5
🚨Postdoctoral position available now! 🚨We have an immediate fully funded position available in cardiac metabolism. We are looking for a highly motivated person to lead our animal model work in oxidative metabolism in heart! Pay is competitive with benefits offered. 1/2
16
29
51
AHH!! My primary thesis work is finally out! Tweetorial to come...
New online! ACAD10 and ACAD11 enable mammalian 4-hydroxy acid lipid catabolism https://t.co/JxDn3pT7lW
13
12
78
Strong work! One of my most favorite auxotrophic papers was from @JaviGBermudez and @KivancBirsoy, can't wait to read this one.
My lab's first paper is out in @Nature. We show that lipoprotein uptake protects tumors from ferroptosis by delivering the lipid antioxidant α-tocopherol. Surprisingly, tumors use sulfated glycosaminoglycans—not canonical receptors—to capture lipoproteins.
0
0
2
Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀
49
415
2K
Learn more about Boltz-2, the new open source AI model from MIT and Recursion capable of predicting protein binding affinity with unprecedented speed, scale and accuracy. ▪️ Boltz-2 is the first model to combine structure and binding affinity prediction, approaching the accuracy
2
21
94
Today, we’re announcing an important step forward in modeling binding affinity alongside @MIT and a research team led by Regina Barzilay. Boltz-2 is the first open-source co-folding model to combine protein structure and binding affinity predictions – measuring how strongly a
Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀
1
31
133
Today, we’re announcing an important step forward in modeling binding affinity alongside @MIT and a research team led by Regina Barzilay. Boltz-2 is the first open-source co-folding model to combine protein structure and binding affinity predictions – measuring how strongly a
Excited to unveil Boltz-2, our new model capable not only of predicting structures but also binding affinities! Boltz-2 is the first AI model to approach the performance of FEP simulations while being more than 1000x faster! All open-sourced under MIT license! A thread… 🤗🚀
1
31
133
What if we could map the surface features that make a protein degradable? At Monte Rosa, we’re doing just that – creating ‘glueprints’ to rationally design molecular glue degraders for previously undruggable targets. Our latest preprint explains how: https://t.co/JJBOwWZ63g
1
1
2
NEW: Google’s bet on AI in drug discovery just got a lot bigger. My latest with @ky_lahucik on Isomorphic's $600 million round — the largest in biotech so far in 2025: https://t.co/7Hke5HahJT
endpoints.news
Isomorphic Labs, one of the leading AI-driven drug discovery companies within Alphabet, has reeled in $600 million in external financing as it nears the clinic.
1
13
29
Come visit with @RecursionPharma at AACR!
Recursion at AACR: Pursuing novel, first-in-class medicines with a suite of AI-enabled platform technologies. 🔹 Recursion is presenting 3 posters and will be featured as part of 1 collaborator poster at the upcoming @AACR Annual Meeting April 25-30 in Chicago showcasing our
0
0
1
The Recursion $RXRX Pi3k preclinical molecule REC-7735 just revealed - as good, if not better, than the Scorpion molecule STX-478 that received so much attention recently when it was acquired by Lilly for up to $2.5Bn.
9
5
63
Today, we are announcing a new pre-seed venture fund – Altitude Lab Fund – to support early-stage biotech startups facing the loss of SBIR grants due to recent federal funding policy shifts which have left many biotech founders in limbo. I wrote about why these funds are so
22
63
372
It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis
1K
5K
19K
Yikes!
Trump blocks NIH review. I’m on a study section to review cancer grants but received this email today: NIH has paused all communication, as directed by the new administration (e.g. https://t.co/KD9vnuN3ac ), and that apparently includes a pause for all study section meetings
0
0
0
Long term outcomes from #KATHERINE out in @NEJM. Post-neoadjuvant escalation of therapy with a HER2 ADC (T-DM1) in patients with HER2+ breast cancer and residual disease meaningfully improves 7-year iDFS (Δ 13.7%) and OS (Δ 4.7%). Congrats to the authors! https://t.co/vRzBoREULK
3
53
182